1
|
Višnjić D, Lalić H, Dembitz V, Tomić B, Smoljo T. AICAr, a Widely Used AMPK Activator with Important AMPK-Independent Effects: A Systematic Review. Cells 2021. [PMID: 34064363 DOI: 10.3390/cellsl0051095] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/08/2023] Open
Abstract
5-Aminoimidazole-4-carboxamide ribonucleoside (AICAr) has been one of the most commonly used pharmacological modulators of AMPK activity. The majority of early studies on the role of AMPK, both in the physiological regulation of metabolism and in cancer pathogenesis, were based solely on the use of AICAr as an AMPK-activator. Even with more complex models of AMPK downregulation and knockout being introduced, AICAr remained a regular starting point for many studies focusing on AMPK biology. However, there is an increasing number of studies showing that numerous AICAr effects, previously attributed to AMPK activation, are in fact AMPK-independent. This review aims to give an overview of the present knowledge on AMPK-dependent and AMPK-independent effects of AICAr on metabolism, hypoxia, exercise, nucleotide synthesis, and cancer, calling for caution in the interpretation of AICAr-based studies in the context of understanding AMPK signaling pathway.
Collapse
Affiliation(s)
- Dora Višnjić
- Laboratory of Cell Biology, Croatian Institute for Brain Research, University of Zagreb School of Medicine, 10000 Zagreb, Croatia
- Department of Physiology, University of Zagreb School of Medicine, 10000 Zagreb, Croatia
| | - Hrvoje Lalić
- Laboratory of Cell Biology, Croatian Institute for Brain Research, University of Zagreb School of Medicine, 10000 Zagreb, Croatia
- Department of Physiology, University of Zagreb School of Medicine, 10000 Zagreb, Croatia
| | - Vilma Dembitz
- Laboratory of Cell Biology, Croatian Institute for Brain Research, University of Zagreb School of Medicine, 10000 Zagreb, Croatia
- Department of Physiology, University of Zagreb School of Medicine, 10000 Zagreb, Croatia
| | - Barbara Tomić
- Laboratory of Cell Biology, Croatian Institute for Brain Research, University of Zagreb School of Medicine, 10000 Zagreb, Croatia
- Department of Physiology, University of Zagreb School of Medicine, 10000 Zagreb, Croatia
| | - Tomislav Smoljo
- Laboratory of Cell Biology, Croatian Institute for Brain Research, University of Zagreb School of Medicine, 10000 Zagreb, Croatia
- Department of Physiology, University of Zagreb School of Medicine, 10000 Zagreb, Croatia
| |
Collapse
|
2
|
AICAr, a Widely Used AMPK Activator with Important AMPK-Independent Effects: A Systematic Review. Cells 2021; 10:cells10051095. [PMID: 34064363 PMCID: PMC8147799 DOI: 10.3390/cells10051095] [Citation(s) in RCA: 51] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2021] [Revised: 04/21/2021] [Accepted: 05/01/2021] [Indexed: 12/24/2022] Open
Abstract
5-Aminoimidazole-4-carboxamide ribonucleoside (AICAr) has been one of the most commonly used pharmacological modulators of AMPK activity. The majority of early studies on the role of AMPK, both in the physiological regulation of metabolism and in cancer pathogenesis, were based solely on the use of AICAr as an AMPK-activator. Even with more complex models of AMPK downregulation and knockout being introduced, AICAr remained a regular starting point for many studies focusing on AMPK biology. However, there is an increasing number of studies showing that numerous AICAr effects, previously attributed to AMPK activation, are in fact AMPK-independent. This review aims to give an overview of the present knowledge on AMPK-dependent and AMPK-independent effects of AICAr on metabolism, hypoxia, exercise, nucleotide synthesis, and cancer, calling for caution in the interpretation of AICAr-based studies in the context of understanding AMPK signaling pathway.
Collapse
|
3
|
Saint-Marc C, Ceschin J, Almyre C, Pinson B, Daignan-Fornier B. Genetic investigation of purine nucleotide imbalance in Saccharomyces cerevisiae. Curr Genet 2020; 66:1163-1177. [PMID: 32780163 DOI: 10.1007/s00294-020-01101-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2020] [Revised: 07/21/2020] [Accepted: 08/06/2020] [Indexed: 11/28/2022]
Abstract
Because metabolism is a complex balanced process involving multiple enzymes, understanding how organisms compensate for transient or permanent metabolic imbalance is a challenging task that can be more easily achieved in simpler unicellular organisms. The metabolic balance results not only from the combination of individual enzymatic properties, regulation of enzyme abundance, but also from the architecture of the metabolic network offering multiple interconversion alternatives. Although metabolic networks are generally highly resilient to perturbations, metabolic imbalance resulting from enzymatic defect and specific environmental conditions can be designed experimentally and studied. Starting with a double amd1 aah1 mutant that severely and conditionally affects yeast growth, we carefully characterized the metabolic shuffle associated with this defect. We established that the GTP decrease resulting in an adenylic/guanylic nucleotide imbalance was responsible for the growth defect. Identification of several gene dosage suppressors revealed that TAT1, encoding an amino acid transporter, is a robust suppressor of the amd1 aah1 growth defect. We show that TAT1 suppression occurs through replenishment of the GTP pool in a process requiring the histidine biosynthesis pathway. Importantly, we establish that a tat1 mutant exhibits synthetic sickness when combined with an amd1 mutant and that both components of this synthetic phenotype can be suppressed by specific gene dosage suppressors. Together our data point to a strong phenotypic connection between amino acid uptake and GTP synthesis, a connection that could open perspectives for future treatment of related human defects, previously reported as etiologically highly conserved.
Collapse
Affiliation(s)
- Christelle Saint-Marc
- IBGC, UMR 5095, Université de Bordeaux, Bordeaux, France.,Centre National de la Recherche Scientifique IBGC, UMR 5095, Bordeaux, France
| | - Johanna Ceschin
- IBGC, UMR 5095, Université de Bordeaux, Bordeaux, France.,Centre National de la Recherche Scientifique IBGC, UMR 5095, Bordeaux, France
| | - Claire Almyre
- IBGC, UMR 5095, Université de Bordeaux, Bordeaux, France.,Centre National de la Recherche Scientifique IBGC, UMR 5095, Bordeaux, France
| | - Benoît Pinson
- IBGC, UMR 5095, Université de Bordeaux, Bordeaux, France.,Centre National de la Recherche Scientifique IBGC, UMR 5095, Bordeaux, France
| | - Bertrand Daignan-Fornier
- IBGC, UMR 5095, Université de Bordeaux, Bordeaux, France. .,Centre National de la Recherche Scientifique IBGC, UMR 5095, Bordeaux, France.
| |
Collapse
|
4
|
Whether AICAR in Pregnancy or Lactation Prevents Hypertension Programmed by High Saturated Fat Diet: A Pilot Study. Nutrients 2020; 12:nu12020448. [PMID: 32053935 PMCID: PMC7071394 DOI: 10.3390/nu12020448] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2020] [Revised: 02/07/2020] [Accepted: 02/08/2020] [Indexed: 12/29/2022] Open
Abstract
High consumption of saturated fats links to the development of hypertension. AMP-activated protein kinase (AMPK), a nutrient-sensing signal, is involved in the pathogenesis of hypertension. We examined whether early intervention with a direct AMPK activator 5-aminoimidazole-4-carboxamide riboside (AICAR) during pregnancy or lactation can protect adult male offspring against hypertension programmed by high saturated fat consumption via regulation of nutrient sensing signals, nitric oxide (NO) pathway, and oxidative stress. Pregnant Sprague-Dawley rats received regular chow or high saturated fat diet (HFD) throughout pregnancy and lactation. AICAR treatment was introduced by intraperitoneal injection at 50 mg/kg twice a day for 3 weeks throughout the pregnancy period (AICAR/P) or lactation period (AICAR/L). Male offspring (n = 7-8/group) were assigned to five groups: control, HFD, AICAR/P, HFD + AICAR/L, and HFD + AICAR/P. Male offspring were killed at 16 weeks of age. HFD caused hypertension and obesity in male adult offspring, which could be prevented by AICAR therapy used either during pregnancy or lactation. As a result, we demonstrated that HFD downregulated AMPK/SIRT1/PGC-1α pathway in offspring kidneys. In contrast, AICAR therapy in pregnancy and, to a greater extent, in lactation activated AMPK signaling pathway. The beneficial effects of AICAR therapy in pregnancy is related to restoration of NO pathway. While AICAR uses in pregnancy and lactation both diminished oxidative stress induced by HFD. Our results highlighted that pharmacological AMPK activation might be a promising strategy to prevent hypertension programmed by excessive consumption of high-fat food.
Collapse
|
5
|
Pinson B, Ceschin J, Saint-Marc C, Daignan-Fornier B. Dual control of NAD + synthesis by purine metabolites in yeast. eLife 2019; 8:43808. [PMID: 30860478 PMCID: PMC6430606 DOI: 10.7554/elife.43808] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2018] [Accepted: 03/11/2019] [Indexed: 12/13/2022] Open
Abstract
Metabolism is a highly integrated process resulting in energy and biomass production. While individual metabolic routes are well characterized, the mechanisms ensuring crosstalk between pathways are poorly described, although they are crucial for homeostasis. Here, we establish a co-regulation of purine and pyridine metabolism in response to external adenine through two separable mechanisms. First, adenine depletion promotes transcriptional upregulation of the de novo NAD+ biosynthesis genes by a mechanism requiring the key-purine intermediates ZMP/SZMP and the Bas1/Pho2 transcription factors. Second, adenine supplementation favors the pyridine salvage route resulting in an ATP-dependent increase of intracellular NAD+. This control operates at the level of the nicotinic acid mononucleotide adenylyl-transferase Nma1 and can be bypassed by overexpressing this enzyme. Therefore, in yeast, pyridine metabolism is under the dual control of ZMP/SZMP and ATP, revealing a much wider regulatory role for these intermediate metabolites in an integrated biosynthesis network.
Collapse
Affiliation(s)
- Benoît Pinson
- IBGCUniversité de Bordeaux UMR 5095BordeauxFrance
- Centre National de la Recherche Scientifique IBGC UMR 5095BordeauxFrance
| | - Johanna Ceschin
- IBGCUniversité de Bordeaux UMR 5095BordeauxFrance
- Centre National de la Recherche Scientifique IBGC UMR 5095BordeauxFrance
| | - Christelle Saint-Marc
- IBGCUniversité de Bordeaux UMR 5095BordeauxFrance
- Centre National de la Recherche Scientifique IBGC UMR 5095BordeauxFrance
| | | |
Collapse
|
6
|
Daignan-Fornier B, Pinson B. Yeast to Study Human Purine Metabolism Diseases. Cells 2019; 8:cells8010067. [PMID: 30658520 PMCID: PMC6356901 DOI: 10.3390/cells8010067] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2019] [Revised: 01/15/2019] [Accepted: 01/15/2019] [Indexed: 02/04/2023] Open
Abstract
Purine nucleotides are involved in a multitude of cellular processes, and the dysfunction of purine metabolism has drastic physiological and pathological consequences. Accordingly, several genetic disorders associated with defective purine metabolism have been reported. The etiology of these diseases is poorly understood and simple model organisms, such as yeast, have proved valuable to provide a more comprehensive view of the metabolic consequences caused by the identified mutations. In this review, we present results obtained with the yeast Saccharomyces cerevisiae to exemplify how a eukaryotic unicellular organism can offer highly relevant information for identifying the molecular basis of complex human diseases. Overall, purine metabolism illustrates a remarkable conservation of genes, functions and phenotypes between humans and yeast.
Collapse
Affiliation(s)
- Bertrand Daignan-Fornier
- Université de Bordeaux IBGC UMR 5095 1, rue Camille Saint-Saëns, F-33077 Bordeaux, France.
- Centre National de la Recherche Scientifique IBGC UMR 5095 1, rue Camille Saint-Saëns, F-33077 Bordeaux, France.
| | - Benoît Pinson
- Université de Bordeaux IBGC UMR 5095 1, rue Camille Saint-Saëns, F-33077 Bordeaux, France.
- Centre National de la Recherche Scientifique IBGC UMR 5095 1, rue Camille Saint-Saëns, F-33077 Bordeaux, France.
| |
Collapse
|
7
|
Douillet DC, Pinson B, Ceschin J, Hürlimann HC, Saint-Marc C, Laporte D, Claverol S, Konrad M, Bonneu M, Daignan-Fornier B. Metabolomics and proteomics identify the toxic form and the associated cellular binding targets of the anti-proliferative drug AICAR. J Biol Chem 2018; 294:805-815. [PMID: 30478173 DOI: 10.1074/jbc.ra118.004964] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2018] [Revised: 11/09/2018] [Indexed: 12/14/2022] Open
Abstract
5-Aminoimidazole-4-carboxamide 1-β-d-ribofuranoside (AICAR, or acadesine) is a precursor of the monophosphate derivative 5-amino-4-imidazole carboxamide ribonucleoside 5'-phosphate (ZMP), an intermediate in de novo purine biosynthesis. AICAR proved to have promising anti-proliferative properties, although the molecular basis of its toxicity is poorly understood. To exert cytotoxicity, AICAR needs to be metabolized, but the AICAR-derived toxic metabolite was not identified. Here, we show that ZMP is the major toxic derivative of AICAR in yeast and establish that its metabolization to succinyl-ZMP, ZDP, or ZTP (di- and triphosphate derivatives of AICAR) strongly reduced its toxicity. Affinity chromatography identified 74 ZMP-binding proteins, including 41 that were found neither as AMP nor as AICAR or succinyl-ZMP binders. Overexpression of karyopherin-β Kap123, one of the ZMP-specific binders, partially rescued AICAR toxicity. Quantitative proteomic analyses revealed 57 proteins significantly less abundant on nuclei-enriched fractions from AICAR-fed cells, this effect being compensated by overexpression of KAP123 for 15 of them. These results reveal nuclear protein trafficking as a function affected by AICAR.
Collapse
Affiliation(s)
- Delphine C Douillet
- From the Université de Bordeaux, IBGC UMR 5095, F-33077 Bordeaux, France.,the Centre National de la Recherche Scientifique, IBGC UMR 5095, F-33077 Bordeaux, France
| | - Benoît Pinson
- From the Université de Bordeaux, IBGC UMR 5095, F-33077 Bordeaux, France.,the Centre National de la Recherche Scientifique, IBGC UMR 5095, F-33077 Bordeaux, France
| | - Johanna Ceschin
- From the Université de Bordeaux, IBGC UMR 5095, F-33077 Bordeaux, France.,the Centre National de la Recherche Scientifique, IBGC UMR 5095, F-33077 Bordeaux, France
| | - Hans C Hürlimann
- From the Université de Bordeaux, IBGC UMR 5095, F-33077 Bordeaux, France.,the Centre National de la Recherche Scientifique, IBGC UMR 5095, F-33077 Bordeaux, France
| | - Christelle Saint-Marc
- From the Université de Bordeaux, IBGC UMR 5095, F-33077 Bordeaux, France.,the Centre National de la Recherche Scientifique, IBGC UMR 5095, F-33077 Bordeaux, France
| | - Damien Laporte
- From the Université de Bordeaux, IBGC UMR 5095, F-33077 Bordeaux, France.,the Centre National de la Recherche Scientifique, IBGC UMR 5095, F-33077 Bordeaux, France
| | - Stéphane Claverol
- the University of Bordeaux, Bordeaux INP, Plateforme Proteome, F-33076 Bordeaux, France, and
| | - Manfred Konrad
- the Max-Planck-Institute for Biophysical Chemistry, D-37077 Goettingen, Germany
| | - Marc Bonneu
- the University of Bordeaux, Bordeaux INP, Plateforme Proteome, F-33076 Bordeaux, France, and
| | - Bertrand Daignan-Fornier
- From the Université de Bordeaux, IBGC UMR 5095, F-33077 Bordeaux, France, .,the Centre National de la Recherche Scientifique, IBGC UMR 5095, F-33077 Bordeaux, France
| |
Collapse
|
8
|
Albrecht D, Hürlimann HC, Ceschin J, Saint-Marc C, Pinson B, Daignan-Fornier B. Multiple chemo-genetic interactions between a toxic metabolite and the ubiquitin pathway in yeast. Curr Genet 2018; 64:1275-1286. [PMID: 29721631 DOI: 10.1007/s00294-018-0843-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2018] [Revised: 04/17/2018] [Accepted: 04/26/2018] [Indexed: 12/21/2022]
Abstract
AICAR is the precursor of ZMP, a metabolite with antiproliferative properties in yeast and human. We aim at understanding how AICAR (and its active form ZMP) affects essential cellular processes. In this work, we found that ZMP accumulation is synthetic lethal with a hypomorphic allele of the ubiquitin-activating enzyme Uba1. A search for gene-dosage suppressors revealed that ubiquitin overexpression was sufficient to restore growth of the uba1 mutant upon AICAR treatment, suggesting that the ubiquitin pool is critical for cells to cope with AICAR. Accordingly, two mutants with constitutive low ubiquitin, ubp6 and doa1, were highly sensitive to AICAR, a phenotype that could be suppressed by ubiquitin overexpression. We established, by genetic means, that these new AICAR-sensitive mutants act in a different pathway from the rad6/bre1 mutants which were previously reported as sensitive to AICAR (Albrecht et al., Genetics 204:1447-1460, 2016). Two ubiquitin-conjugating enzymes (Ubc4 and Cdc34) and a ubiquitin ligase (Cdc4) were found to contribute to the ability of cells to cope with ZMP. This study illustrates the complexity of chemo-genetic interactions and shows how genetic analyses allow deciphering the implicated pathways, the individual gene effects, and their combined phenotypic contribution. Based on additivity and suppression patterns, we conclude that AICAR treatment shows synthetic interactions with distinct branches of the yeast ubiquitin pathway.
Collapse
Affiliation(s)
- Delphine Albrecht
- Université de Bordeaux, IBGC UMR 5095, 1 rue Camille Saint-Saëns, 33077, Bordeaux, France
- Centre National de la Recherche Scientifique, IBGC UMR 5095, 1 rue Camille Saint-Saëns, 33077, Bordeaux, France
| | - Hans C Hürlimann
- Université de Bordeaux, IBGC UMR 5095, 1 rue Camille Saint-Saëns, 33077, Bordeaux, France
- Centre National de la Recherche Scientifique, IBGC UMR 5095, 1 rue Camille Saint-Saëns, 33077, Bordeaux, France
- Institut für Biologie, Martin-Luther Universität, Universität Halle-Wittenberg, Weinbergweg 10, 06120, Halle (Saale), Germany
| | - Johanna Ceschin
- Université de Bordeaux, IBGC UMR 5095, 1 rue Camille Saint-Saëns, 33077, Bordeaux, France
- Centre National de la Recherche Scientifique, IBGC UMR 5095, 1 rue Camille Saint-Saëns, 33077, Bordeaux, France
| | - Christelle Saint-Marc
- Université de Bordeaux, IBGC UMR 5095, 1 rue Camille Saint-Saëns, 33077, Bordeaux, France
- Centre National de la Recherche Scientifique, IBGC UMR 5095, 1 rue Camille Saint-Saëns, 33077, Bordeaux, France
| | - Benoît Pinson
- Université de Bordeaux, IBGC UMR 5095, 1 rue Camille Saint-Saëns, 33077, Bordeaux, France
- Centre National de la Recherche Scientifique, IBGC UMR 5095, 1 rue Camille Saint-Saëns, 33077, Bordeaux, France
| | - Bertrand Daignan-Fornier
- Université de Bordeaux, IBGC UMR 5095, 1 rue Camille Saint-Saëns, 33077, Bordeaux, France.
- Centre National de la Recherche Scientifique, IBGC UMR 5095, 1 rue Camille Saint-Saëns, 33077, Bordeaux, France.
- Institut de Biochimie et Génétique Cellulaires, CNRS UMR 5095, 1 rue C. Saint-Saëns CS 61390, 33077, Bordeaux, France.
| |
Collapse
|
9
|
Chemo-Genetic Interactions Between Histone Modification and the Antiproliferation Drug AICAR Are Conserved in Yeast and Humans. Genetics 2016; 204:1447-1460. [PMID: 27707786 PMCID: PMC5161278 DOI: 10.1534/genetics.116.192518] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2016] [Accepted: 09/26/2016] [Indexed: 12/27/2022] Open
Abstract
Identifying synthetic lethal interactions has emerged as a promising new therapeutic approach aimed at targeting cancer cells directly. Here, we used the yeast Saccharomyces cerevisiae as a simple eukaryotic model to screen for mutations resulting in a synthetic lethality with 5-amino-4-imidazole carboxamide ribonucleoside (AICAR) treatment. Indeed, AICAR has been reported to inhibit the proliferation of multiple cancer cell lines. Here, we found that loss of several histone-modifying enzymes, including Bre1 (histone H2B ubiquitination) and Set1 (histone H3 lysine 4 methylation), greatly enhanced AICAR inhibition on growth via the combined effects of both the drug and mutations on G1 cyclins. Our results point to AICAR impacting on Cln3 subcellular localization and at the Cln1 protein level, while the bre1 or set1 deletion affected CLN1 and CLN2 expression. As a consequence, AICAR and bre1/set1 deletions jointly affected all three G1 cyclins (Cln1, Cln2, and Cln3), leading to a condition known to result in synthetic lethality. Significantly, these chemo-genetic synthetic interactions were conserved in human HCT116 cells. Indeed, knock-down of RNF40, ASH2L, and KMT2D/MLL2 induced a highly significant increase in AICAR sensitivity. Given that KMT2D/MLL2 is mutated at high frequency in a variety of cancers, this synthetic lethal interaction has an interesting therapeutic potential.
Collapse
|
10
|
Tschirner SK, Bähre H, Kaever A, Schneider EH, Seifert R, Kaever V. Non-targeted metabolomics by high resolution mass spectrometry in HPRT knockout mice. Life Sci 2016; 156:68-73. [PMID: 27221022 DOI: 10.1016/j.lfs.2016.05.031] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2015] [Revised: 04/07/2016] [Accepted: 05/20/2016] [Indexed: 12/31/2022]
Abstract
AIMS Lesch-Nyhan disease (LND) is characterized by hyperuricemia as well as neurological and neuropsychiatric symptoms including repetitive self-injurious behavior. Symptoms are caused by a deficiency of the enzyme hypoxanthine-guanine phosphoribosyltransferase (HPRT) as a result of a mutation on the X chromosome. To elucidate the pathophysiology of LND, we performed a metabolite screening for brain and serum extracts from HPRT knockout mice as an animal model for LND. MAIN METHODS Analyses were performed by high performance liquid chromatography (HPLC)-coupled quadrupole time-of-flight mass spectrometry (QTOF-MS). KEY FINDINGS In brain extracts, we found six metabolites with significantly different contents in wild-type and HPRT-deficient mice. Two compounds we could identify as 5-aminoimidazole-4-carboxamide ribotide (AICAR) and 1-methylimidazole-4-acetic acid (1-MI4AA). Whereas AICAR was accumulated in brains of HPRT knockout mice, 1-MI4AA was decreased in these mice. SIGNIFICANCE Both metabolites play a role in histidine metabolism and, as a consequence, histamine metabolism. AICAR, in addition, is part of the purine metabolism. Our findings may help to better understand the mechanisms leading to the behavioral phenotype of LND.
Collapse
Affiliation(s)
- Sarah K Tschirner
- Institute of Pharmacology, Hannover Medical School, Carl-Neuberg-Str. 1, D-30625 Hannover, Germany.
| | - Heike Bähre
- Institute of Pharmacology, Hannover Medical School, Carl-Neuberg-Str. 1, D-30625 Hannover, Germany; Research Core Unit Metabolomics, Hannover Medical School, Carl-Neuberg-Str. 1, D-30625 Hannover, Germany.
| | - Alexander Kaever
- Department of Bioinformatics, Institute of Microbiology and Genetics, Georg-August-University Göttingen, Goldschmidtstr. 1, D-37077 Göttingen, Germany.
| | - Erich H Schneider
- Institute of Pharmacology, Hannover Medical School, Carl-Neuberg-Str. 1, D-30625 Hannover, Germany.
| | - Roland Seifert
- Institute of Pharmacology, Hannover Medical School, Carl-Neuberg-Str. 1, D-30625 Hannover, Germany.
| | - Volkhard Kaever
- Institute of Pharmacology, Hannover Medical School, Carl-Neuberg-Str. 1, D-30625 Hannover, Germany; Research Core Unit Metabolomics, Hannover Medical School, Carl-Neuberg-Str. 1, D-30625 Hannover, Germany.
| |
Collapse
|